Regulation of Thrombocyte Adenylate Cyclase Activity in Terminal Renal Failure

• References

• 1 Michalak E, Walkowiak B, Paradowski M, Cierniewski CS. The decreased circulating platelet mass and its relation to bleeding time. Thromb Haemostas 1991; 65: 11-4
• 2 Vlachoyannis J, Schoeppe W. Adenylate cyclase activity and cAMP content in human platelets in uremia. Eur J Clin Invest 1982; 12: 379-81
• 3 Jacobsson B, Rasnas L, Nyberg G, Bregh CH, Magnusson Y, Hjalmarson A. Abnormality of adenylate cyclase regulation in human platelet membranes in renal failure. Eur J Clin Invest 1985; 15: 75-81
• 4 Lübbecke F, Zschôtzsch S, Mitrovic V, Husseini H, Schlepper M, Lasch H-G, Schütterle G, Wizemann V. Catecholamines and thrombocyte alpha₂-adrenoceptors in patients with acute myocardial infarction. Eur Heart J 1991; 12: 88-91
• 5 Salomon Y. Adenylate cyclase assay. Adv Cycl Nucl Res 1979; 10: 35-55
• 6 Rabiner SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49: 346-51
• 7 Setchenska MS, Bonanou-Tzedaki SA, Arnstein HRV. Independent activation of adenylate cyclase by erythropoietin and isoprenaline. Mol Cell Endocrinol 1988; 56: 199-204
• 8 Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the hemostatic defect of uremia after treatment with recombinant human erythropoietin. Lancet 1987; ii: 1227-9